TNL Mediagene Faces Nasdaq Compliance Issues

TNL Mediagene is under scrutiny by Nasdaq due to low equity. The company received a deficiency letter from the exchange, citing concerns over its compliance with listing requirements.

This is the second report of such an issue for TNL Mediagene on this day, with Nasdaq also flagging the company for listing non-compliance [docs 4, 6].

TNL Mediagene's equity levels have been scrutinized, with Nasdaq requiring a minimum of $2.5 million for continued listing. This is a concern for potential investors, who may consider alternative market-listed media-tech companies.

Companies receiving Nasdaq deficiency letters typically have 45 days to submit a plan for regaining compliance or 180 days to demonstrate that the deficiency has been resolved. If TNL Mediagene (TNMG) fails to restore its equity above the $2.5 million threshold within the allotted timeframe, Nasdaq may initiate delisting proceedings — a development that would significantly impair the stock's liquidity and institutional investor eligibility.